Preparation method of anti-drug resistance compound florfenicol and berberine hydrochloride powder

Abstract

The invention discloses a preparation method of anti-drug resistance compound florfenicol and berberine hydrochloride powder, and belongs to the technical field of medicine preparation. The anti-drug resistance compound florfenicol and berberine hydrochloride powder is prepared from the following raw materials in parts by mass: 1 to 50 parts of florfenicol, 1 to 50 parts of berberine hydrochloride and 0 to 98 parts of starch. The anti-drug-resistance compound florfenicol and berberine hydrochloride powder can well treat various disease infections of aquatic animals, and berberine hydrochloride in the powder can greatly reduce the drug resistance of pathogenic bacteria to florfenicol and enhance the antibacterial activity of florfenicol.

Description

Technical Field

[0001] The invention relates to the technical field of drug preparation, and in particular to a method for preparing a drug resistance-preventing compound florfenicol and berberine hydrochloride powder. Background Art

[0002] Florfenicol is an important broad-spectrum antibiotic widely used in veterinary medicine and aquaculture. It has been approved for marketing in my country since the 1990s and has a history of more than 30 years of application. With the extension of the application time, bacteria gradually develop drug resistance, resulting in a decrease in the antibacterial activity of antibiotics. Florfenicol is no exception. It has developed a relatively wide range of drug resistance in aquatic bacteria, and some minimum inhibitory concentrations have exceeded dozens of PPM. However, florfenicol is still an excellent antibiotic with a broad antibacterial spectrum, low toxicity, and a short withdrawal period. It is favored by a large number of breeding companies and farmers. Therefore, how to reduce bacterial resistance and restore the antibacterial activity of florfenicol is a problem that needs to be solved urgently. Summary of the invention

[0003] The purpose of the present invention is to provide a method for preparing a drug resistance-preventing compound florfenicol and berberine hydrochloride powder to solve the problems existing in the above-mentioned prior art.

[0004] To achieve the above object, the present invention provides the following solutions:

[0005] One of the technical solutions of the present invention: an antibacterial composition, the active ingredients of which include florfenicol and berberine hydrochloride.

[0006] Furthermore, the mass ratio of florfenicol to berberine hydrochloride is (1-50):(1-50).

[0007] The second technical solution of the present invention: an application of the above-mentioned antibacterial composition in the preparation of medicines for preventing and treating pathogenic bacteria.

[0008] The third technical solution of the present invention: an application of the above-mentioned antibacterial composition in the preparation of a drug for preventing and treating drug-resistant Aeromonas hydrophila, drug-resistant Aeromonas veronii or drug-resistant Citrobacter freundii.

[0009] A fourth technical solution of the present invention: use of the above-mentioned antibacterial composition in the preparation of a drug for preventing and treating diseases caused by drug-resistant Aeromonas hydrophila, drug-resistant Aeromonas veronii or drug-resistant Citrobacter freundii;

[0010] The drug-resistant Aeromonas hydrophila, drug-resistant Aeromonas veronii or drug-resistant Citrobacter freundii are florfenicol-resistant Aeromonas hydrophila, Aeromonas veronii or Citrobacter freundii.

[0011] The fifth technical solution of the present invention: The anti-drug resistance compound florfenicol and berberine hydrochloride powder comprises the following raw materials in parts by mass: 1 to 50 parts of florfenicol, 1 to 50 parts of berberine hydrochloride and 0 to 98 parts of starch.

[0012] Furthermore, the anti-resistance compound florfenicol and berberine hydrochloride powder comprises the following raw materials in parts by mass: 10 to 30 parts of florfenicol, 10 to 30 parts of berberine hydrochloride and 40 to 80 parts of starch.

[0013] Technical solution six of the present invention: A method for preparing the above-mentioned anti-drug resistance compound florfenicol and berberine hydrochloride powder, comprising the following steps:

[0014] After florfenicol and berberine hydrochloride are evenly mixed, starch is added and mixed evenly to obtain the anti-resistance compound florfenicol and berberine hydrochloride powder.

[0015] Technical solution seven of the present invention: an application of the above-mentioned anti-resistance compound florfenicol and berberine hydrochloride powder in the preparation of drugs for preventing and treating diseases caused by Aeromonas hydrophila, Aeromonas veronii or Citrobacter freundii.

[0016] Furthermore, the Aeromonas hydrophila, Aeromonas veronii or Citrobacter freundii is a florfenicol-resistant pathogen.

[0017] The present invention discloses the following technical effects:

[0018] The anti-resistance compound florfenicol and berberine hydrochloride powder of the present invention can well treat various disease infections of aquatic animals. The berberine hydrochloride in the powder can greatly reduce the resistance of pathogens to florfenicol and enhance the antibacterial activity of florfenicol.

[0019] The anti-drug resistance compound florfenicol and berberine hydrochloride powder of the present invention has a simple preparation process and readily available raw materials, is suitable for industrial large-scale production, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0021] Figure 1 This is a chessboard pattern diagram. DETAILED DESCRIPTION

[0022] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0023] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0024] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0025] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.

[0026] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0027] The “parts” described in the following examples are all “parts by weight”.

[0028] The identification results of drug-resistant Aeromonas hydrophila, drug-resistant Aeromonas veronii, and drug-resistant Citrobacter freundii are as follows:

[0029] (1) Drug-resistant Aeromonas hydrophila from yellow catfish

[0030]

[0031]

[0032] (2) Drug-resistant Aeromonas veronii from yellow catfish

[0033]

[0034]

[0035] (3) Drug-resistant Citrobacter freundii from Procambarus clarkii

[0036]

[0037]

[0038]

[0039] Example 1

[0040] Berberine hydrochloride increases the bactericidal ability of florfenicol against drug-resistant Aeromonas hydrophila:

[0041] (1) The minimum inhibitory concentration (minimum concentration for sterile growth) of berberine hydrochloride and florfenicol against drug-resistant Aeromonas hydrophila was determined by microdilution method, specifically:

[0042] First, draw 200 μL of drug working solution (the concentration of berberine hydrochloride drug working solution is 2048 μg / mL, which is prepared by diluting the berberine hydrochloride standard stock solution (concentration 5120 μg / mL) with sterilized MH broth; the concentration of florfenicol drug working solution is 256 μg / mL, which is prepared by diluting the florfenicol standard stock solution (concentration 2560 μg / mL) with sterilized MH broth) and add it to the preset maximum drug concentration well, and then add 100 μL of sterile MH broth to the remaining wells, then draw 100 μL of drug working solution from the maximum drug concentration well and add it to the second well. After repeatedly pipetting and beating 5 times to mix, draw 100 μL and add it to the third well. Make multiple dilutions in sequence and discard the 100 μL of liquid aspirated from the last well. At this time, each well contains 100 μL of drug-containing broth, in which the concentration of berberine hydrochloride is 1024 μg / mL to 0.50 μg / mL, and the concentration of florfenicol is 128 μg / mL to 0.0313 μg / mL. Add 100 μL of drug-resistant Aeromonas hydrophila bacterial suspension (containing 10 7 cfu / mL), and then cultured in a constant temperature incubator (28°C) for at least 24 hours, and then observed whether there were clear holes. The drug concentration in the clear holes was the minimum concentration for sterile growth, which was the MIC.

[0043] (2) Chessboard method for determining the combined effect of berberine hydrochloride and florfenicol

[0044] Take a 96-well bacterial culture plate, row Y1 and column X1 are the rows and columns for drug A (berberine hydrochloride) and drug B (florfenicol) alone, respectively, and the dosing method is shown in Table 1;

[0045] Drug A was added to wells 2 to 7 of row Y1. The concentrations of drug A were 1 / 32, 1 / 16, 1 / 8, 1 / 4, 1 / 2, and 1 times the MIC (512 μg / mL), 100 μL each of standard drug solutions (referred to as drug A 1 / 32, drug A 1 / 16, drug A 1 / 8, drug A 1 / 4, drug A 1 / 2, and drug A 1);

[0046] Add drug B to wells 2 to 7 of column X1. The concentrations of drug B are 1 / 4, 1 / 2, 1, 2, 4, and 8 times the MIC (16 μg / mL), 100 μL of standard drug solution (referred to as drug B 1 / 4, drug B 1 / 2, drug B 1, drug B 2, drug B 4, and drug B 8);

[0047] Drug A was also added to wells 2 to 7 of rows Y2 to 7. The concentrations of drug A were 1 / 16, 1 / 8, 1 / 4, 1 / 2, 1, and 2 times the MIC (512 μg / mL), 50 μL each of standard drug solutions;

[0048] Drug B was also added to wells 2 to 7 of columns X2 to 7. The concentrations of drug B were 50 μL of standard drug solutions that were 1 / 2, 1, 2, 4, 8, and 16 times the MIC (16 μg / mL), respectively.

[0049] Add 200 μL of the bacterial suspension of drug-resistant Aeromonas hydrophila (containing 10 7 cfu / mL), and 100 μL of the bacterial suspension of drug-resistant Aeromonas hydrophila (containing 10 7 cfu / mL), at this time, the total volume of the liquid in the 96-well plate is 200μL, the 96-well plate with the sample is placed in a constant temperature incubator (28℃) for 24-48h, and the drug concentration in the clear well is the minimum concentration for aseptic growth when the drug is used in combination, which is the MIC.

[0050] The results are determined by reading the equivalent midpoint method: all tubes along the 0-point angle bisector are equivalent midpoint tubes, and the lowest concentration of sterile growth is read as point 1. The point on the X-axis corresponding to this point is MICA (MIC for drug A compound), and the point on the Y-axis is MICB (MIC for drug B compound). The partial concentration inhibition index (FIC) is used as the basis for the combined drug sensitivity test, and the calculation formula is as follows:

[0051]

[0052] FIC index ≤ 0.5 indicates synergistic effect; FIC index 0.5-1 indicates additive effect; FIC index 1-2 indicates irrelevant effect; FIC index > 2 indicates antagonistic effect.

[0053] Table 1 Dosing method

[0054]

[0055]

[0056] The results showed that the MIC of berberine hydrochloride against drug-resistant Aeromonas hydrophila was 512 μg / mL, and the MIC of florfenicol against drug-resistant Aeromonas hydrophila was 16 μg / mL.

[0057] After berberine hydrochloride was used in combination with florfenicol, the minimum concentrations for sterile growth were 32 μg / mL for berberine hydrochloride and 4 μg / mL for florfenicol, and the combined antibacterial index was 0.313, indicating a synergistic effect.

[0058] Example 2

[0059] Berberine hydrochloride increases the bactericidal ability of florfenicol against drug-resistant Aeromonas veronii:

[0060] Same as Example 1, except that the bacterial suspension of drug-resistant Aeromonas hydrophila (containing 10 7 cfu / mL) was replaced with a bacterial suspension of drug-resistant Aeromonas veronii (containing 10 7 cfu / mL).

[0061] The results showed that the MIC of berberine hydrochloride against drug-resistant Aeromonas veronii was 256 μg / mL, and the MIC of florfenicol against drug-resistant Aeromonas veronii was 16 μg / mL.

[0062] After berberine hydrochloride was used in combination with florfenicol, the minimum concentrations for sterile growth were 8 μg / mL for berberine hydrochloride and 8 μg / mL for florfenicol, and the combined antibacterial index was 0.531, which was an additive effect.

[0063] Example 3

[0064] Berberine hydrochloride increases the bactericidal ability of florfenicol against drug-resistant Citrobacter freundii:

[0065] Same as Example 1, except that the bacterial suspension of drug-resistant Aeromonas hydrophila (containing 10 7 cfu / mL) was replaced with a bacterial suspension of drug-resistant Citrobacter freundii (containing 10 7 cfu / mL).

[0066] The results showed that the MIC of berberine hydrochloride against drug-resistant Citrobacter freundii was 512 μg / mL, and the MIC of florfenicol against drug-resistant Citrobacter freundii was 8 μg / mL.

[0067] After berberine hydrochloride was used in combination with florfenicol, the minimum concentrations for sterile growth were 64 μg / mL for berberine hydrochloride and 4 μg / mL for florfenicol, and the combined antibacterial index was 0.625, which was an additive effect.

[0068] Example 4

[0069] Clinical trials:

[0070] (1) Preparation method of anti-drug resistance compound florfenicol and berberine hydrochloride powder:

[0071] Sieve florfenicol, berberine hydrochloride and starch separately (70 mesh) and set aside;

[0072] Weigh 10 parts of florfenicol and 10 parts of berberine hydrochloride respectively, put them into a mixer in sequence and mix them thoroughly; then add 80 parts of starch into the mixer, mix well and sieve again (24 mesh) to obtain the anti-drug resistance compound florfenicol and berberine hydrochloride powder.

[0073] (2) A total of 150 yellow catfish (average weight 134.6±6.7 g / fish) were randomly divided into five groups, with 30 fish in each group.

[0074] The first group was the blank control group, without any challenge or treatment;

[0075] The second group was the negative control group, which was challenged with drug-resistant Aeromonas veronii from yellow catfish (the challenge time was 2 to 3 days). The challenge method was to inject 0.1 mL of 1×10 8 cfu / mL of resistant Aeromonas veronii bacterial solution, successful attack is manifested by prominent inflammation of the cloaca, distended abdomen, ascites on autopsy, no treatment;

[0076] The third group was treatment group 1, which was challenged with drug-resistant Aeromonas veronii from yellow catfish (the challenge method was the same as above). After successful challenge, florfenicol was given for treatment at a dose of 15 mg / kg, twice a day, for three consecutive days.

[0077] The fourth group was treatment group 2, which was challenged with drug-resistant Aeromonas veronii from yellow catfish (the challenge method was the same as above). After successful challenge, berberine hydrochloride was given for treatment at a dose of 20 mg / kg, twice a day, for three consecutive days.

[0078] The fifth group was treatment group 3, which was challenged with drug-resistant Aeromonas veronii from yellow catfish (the challenge method was the same as above). After successful challenge, the anti-resistance compound florfenicol and berberine hydrochloride powder was given for treatment at a dose of 15 mg / kg (calculated as florfenicol), twice a day for three consecutive days.

[0079] The yellow catfish were observed for 7 days after treatment and the mortality rate was calculated. The results are shown in Table 2.

[0080] Table 2 Test results

[0081] Group Death tail number mortality rate(%) Blank control group 1 3.33 Negative control group 30 100 Treatment Group 1 (Flofenicol) 25 83.33 Treatment Group 2 (Berberine Hydrochloride) 26 86.67 Treatment group 3 (anti-resistance compound florfenicol and berberine hydrochloride powder) 1 3.33

[0082] Example 5

[0083] A total of 150 yellow catfish (average body weight of 140.3±17.2 g / fish) were randomly divided into five groups, with 30 fish in each group.

[0084] The first group was the blank control group, without any challenge or treatment;

[0085] The second group was the negative control group, which was challenged with drug-resistant Aeromonas hydrophila from yellow catfish (the challenge time was 2 to 3 days). The challenge method was to inject 0.1 mL of 1×10 7 cfu / mL of resistant Aeromonas hydrophila liquid, successful attack is manifested by abdominal distension, autopsy reveals intestinal congestion and swelling, no treatment;

[0086] The third group was treatment group 1, which was challenged with drug-resistant Aeromonas hydrophila from yellow catfish (the challenge method was the same as above). After successful challenge, florfenicol was given for treatment at a dose of 15 mg / kg, twice a day, for three consecutive days.

[0087] The fourth group was treatment group 2, which was challenged with drug-resistant Aeromonas hydrophila from yellow catfish (the challenge method was the same as above). After successful challenge, berberine hydrochloride was given for treatment at a dose of 20 mg / kg, twice a day, for three consecutive days.

[0088] The fifth group was treatment group 3, which was challenged with resistant Aeromonas hydrophila from yellow catfish (the challenge method was the same as above). After successful challenge, the anti-resistance compound florfenicol and berberine hydrochloride powder was given for treatment at a dose of 15 mg / kg (calculated as florfenicol), twice a day for three consecutive days.

[0089] The yellow catfish were observed for 7 days after treatment and the mortality rate was calculated. The results are shown in Table 3.

[0090] Table 3 Test results

[0091]

[0092] Example 6

[0093] A total of 150 Procambarus clarkii (average weight 22.1±4.7 g / crawfish) were randomly divided into five groups, with 30 crawfish in each group.

[0094] The first group was the blank control group, without any challenge or treatment;

[0095] The second group was the negative control group, which was challenged with resistant Citrobacter freundii from Procambarus clarkii (the challenge time was 2 to 3 days). The challenge method was to inject 0.1 mL of 1×10 8 cfu / mL of resistant Citrobacter freundii liquid, successful infection is manifested by slow movement of Procambarus clarkii, redness and swelling of the tail, or even ulceration, and no treatment is given;

[0096] The third group was treatment group 1, which was challenged with resistant Citrobacter freundii from Procambarus clarkii (the challenge method was the same as above). After successful challenge, florfenicol was given for treatment at a dose of 15 mg / kg, twice a day, for three consecutive days.

[0097] The fourth group was treatment group 2, which was challenged with resistant Citrobacter freundii from Procambarus clarkii (the challenge method was the same as above). After successful challenge, berberine hydrochloride was given for treatment at a dose of 20 mg / kg, twice a day, for three consecutive days.

[0098] The fifth group was treatment group 3, which was challenged with resistant Citrobacter freundii from Procambarus clarkii (the challenge method was the same as above). After successful challenge, the anti-resistance compound florfenicol and berberine hydrochloride powder was given for treatment at a dose of 15 mg / kg (calculated as florfenicol), twice a day for three consecutive days.

[0099] The crayfish were observed for 7 days after treatment and the mortality rate was calculated. The results are shown in Table 4.

[0100] Table 4 Test results

[0101]

[0102] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. An antibacterial composition, characterized in that The active ingredients include florfenicol and berberine hydrochloride.

2. The antibacterial composition according to claim 1, characterized in that The mass ratio of florfenicol to berberine hydrochloride is (1-50):(1-50).

3. Use of the antibacterial composition according to any one of claims 1 to 2 in the preparation of a drug for preventing and treating pathogenic bacteria.

4. Use of the antibacterial composition according to any one of claims 1 to 2 in the preparation of a medicament for preventing and treating drug-resistant Aeromonas hydrophila, drug-resistant Aeromonas veronii or drug-resistant Citrobacter freundii.

5. Use of the antibacterial composition according to any one of claims 1 to 2 in the preparation of a drug for preventing and treating diseases caused by drug-resistant Aeromonas hydrophila, drug-resistant Aeromonas veronii or drug-resistant Citrobacter freundii, characterized in that: The drug-resistant Aeromonas hydrophila, drug-resistant Aeromonas veronii or drug-resistant Citrobacter freundii are florfenicol-resistant Aeromonas hydrophila, Aeromonas veronii or Citrobacter freundii.

6. A compound florfenicol and berberine hydrochloride powder for preventing drug resistance, characterized in that: The invention comprises the following raw materials in parts by mass: 1 to 50 parts of florfenicol, 1 to 50 parts of berberine hydrochloride and 0 to 98 parts of starch.

7. A method for preparing the anti-resistance compound florfenicol and berberine hydrochloride powder according to claim 6, characterized in that: The following steps are involved: After florfenicol and berberine hydrochloride are evenly mixed, starch is added and mixed evenly to obtain the anti-resistance compound florfenicol and berberine hydrochloride powder.

8. Use of the anti-resistance compound florfenicol and berberine hydrochloride powder according to claim 6 in the preparation of a medicament for preventing and treating diseases caused by Aeromonas hydrophila, Aeromonas veronii or Citrobacter freundii.

9. The use according to claim 8, characterized in that: The Aeromonas hydrophila, Aeromonas veronii or Citrobacter freundii are pathogens resistant to florfenicol.

Images